Published by Josh White on 7th February 2018
(ShareCast News) - Respiratory drug discovery and development company Synairgen announced on Wednesday that the first patients have been dosed in the company's Phase II trial of inhaled SNG001 in patients with chronic obstructive pulmonary disease (COPD).
URL: http://www.digitallook.com/dl/news/story/27034014/...